Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations in parkin are the major cause of early-onset familial Parkinson's disease. To investigate the pathogenic mechanism by which loss of parkin function causes Parkinson's disease, we generated a mouse model bearing a germline disruption in parkin. Parkin-/- mice are viable and exhibit grossly normal brain morphology. Quantitative in vivo microdialysis revealed an increase in extracellular dopamine concentration in the striatum of parkin-/- mice. Intracellular recordings of medium-sized striatal spiny neurons showed that greater currents are required to induce synaptic responses, suggesting a reduction in synaptic excitability in the absence of parkin. Furthermore, parkin-/- mice exhibit deficits in behavioral paradigms sensitive to dysfunction of the nigrostriatal pathway. The number of dopaminergic neurons in the substantia nigra of parkin-/- mice, however, is normal up to the age of 24 months, in contrast to the substantial loss of nigral neurons characteristic of Parkinson's disease. Steady-state levels of CDCrel-1, synphilin-1, and alpha-synuclein, which were identified previously as substrates of the E3 ubiquitin ligase activity of parkin, are unaltered in parkin-/- brains. Together these findings provide the first evidence for a novel role of parkin in dopamine regulation and nigrostriatal function, and a non-essential role of parkin in the survival of nigral neurons in mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, parkin-deficient mice and mice expressing a dominant negative form of Nrdp1 are not reported to have significant neurodegenerative disease171819.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“The lack of reported neurodegeneration in parkin-deficient and Nrdp1 mutant mice171819 makes it unlikely that this interaction explains our finding of neurodegeneration in Clec16a mutant mice.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“Although PINK1 (McWilliams et al, 2018) and PRKN (Goldberg et al, 2003; Perez & Palmiter, 2005) deficiency do not elicit major defects under baseline conditions, defective striatal neural plasticity is observed in prkn− / − mice (Kitada et al, 2009).”
From Autophagy in major human diseases (2021) · cites this paper as Goldberg et al, 2003
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Dunham, N. W., & Miya, T. S. (1957) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030460322 · Cited by 1,716
Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433
Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L., & Bland, S. T. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00005-8 · Cited by 1,354
Self-citationNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Research works printed but not linked: 4
- Tanner, 1990, Neurology, 40, 17
- Parsons, 1994, Crit. Rev. Neurobiol., 8, 189
- Walsh, 1992, J. Pharmacol. Exp. Ther., 263, 617
- Schallert, 1988, Vol. 515, 108
Cited by
Items 601–700 of 913
Stauch, K. L., Totusek, S., Trease, A. J., Estrella, L. D., Emanuel, K. M., Fangmeier, A., & Fox, H. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-38484-0 · Cited by 16
von Collenberg, C. R., Schmitt, D., Rülicke, T., Sendtner, M., Blum, R., & Buchner, E. (2019) · Biology Open · doi:10.1242/bio.042366 · Cited by 15
“…in the OF is suggestive of a specific motor initiation problem that is distinct from overall hypoactivity or anxiety-like behaviour typically observed in genetic mouse models for Parkinson ’ s disease (Chesselet and Richter, 2011; Goldberg et al., 2003; Lam et al., 2011; Taylor et al., 2010).”
Overview of Mouse Models of Parkinson's Disease
Bobela, W., Zheng, L., & Schneider, B. L. (2014) · Current Protocols in Mouse Biology · doi:10.1002/9780470942390.mo140092 · Cited by 14
Shen, Y., Guo, X., Han, C., Wan, F. J., Ma, K., Guo, S., Wang, L., Xia, Y. F., Liu, L., Lin, Z., et al. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2549-2 · Cited by 15
De novo tetrahydrobiopterin biosynthesis is impaired in the inflammed striatum of parkin(−/−) mice
Martins, R. D. P., Glaser, V., Aguiar, A. S., Ferreira, P. M. D. P., Ghisoni, K., Scheffer, D. D. L., Lanfumey, L., Raisman‐Vozari, R., Corti, O., Paul, A. L. D., et al. (2018) · Cell Biology International · doi:10.1002/cbin.10969 · Cited by 14
“The parkin knockout mice (parkin / ), by deletion of exon 3, for example, display normal morphology, a normal number of dopaminergic neurons (Goldberg et al., 2003; FrankCannon et al., 2008), mild mitochondrial alterations or oxidative damage (Palacino et al.”
BackgroundResultInfluentialHess, E. J., & Jinnah, H. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00027-5 · Cited by 15
Mukkala, A. N., Petrut, R., Goldfarb, R., Beroncal, E. L., Leung, C. H., Khan, Z. R., Ailenberg, M., Jerkić, M., Andreazza, A. C., Rhind, S. G., et al. (2023) · Mitochondrion · doi:10.1016/j.mito.2023.03.002 · Cited by 14
Diverse Functions of Parkin in Midbrain Dopaminergic Neurons
Song, P., & Krainc, D. (2024) · Movement Disorders · doi:10.1002/mds.29890 · Cited by 13
“However, increased spontaneous dopamine release was detected in nigral neurons in 8 to 9 months parkin knock-out mice, 35 whereas the dopamine release was decreased in 3 to 9 and 12 months parkin knock-out mice.”
Can parkin be a target for future treatment of Parkinson's disease?
Kubo, S., Hatano, T., Takanashi, M., & Hattori, N. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.827173 · Cited by 15
“Two exon 3-disrupted knockouts show subtle motor and cognitive deficits, inhibition of amphetamineinduced dopamine release and glutamate neurotransmission, and abnormal dopamine metabolism, but no loss of substantia nigra or locus coeruleus catecholaminergic neurons [70,71].”
BackgroundInfluentialAnimal Models of Autosomal Recessive Parkinsonism
Bastioli, G., Regoni, M., Cazzaniga, F. A., Luca, C. M. G. D., Bistaffa, E., Zanetti, L., Moda, F., Valtorta, F., & Sassone, J. (2021) · Biomedicines · doi:10.3390/biomedicines9070812 · Cited by 13
Klonarakis, M., Vos, M. D., Woo, E. K., Ralph, L. T., Thacker, J. S., & Gil‐Mohapel, J. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104541 · Cited by 15
Parkin deficiency exacerbates fasting-induced skeletal muscle wasting in mice
Peker, N., Sharma, M., & Kambadur, R. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00419-3 · Cited by 14
Rompuy, A. V., Oliveras-Salvá, M., der Perren, A. V., Corti, O., den Haute, C. V., & Baekelandt, V. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0017-8 · Cited by 14
“On one hand it has been reported that the unmodified form of α-SYN does not interact with parkin [18] and no accumulation of α-SYN was detected in the brain of parkin knockout (parkin) mice [19-21].”
BackgroundSassone, J., Valtorta, F., & Ciammola, A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00273 · Cited by 15
Alterations of PINK1-PRKN signaling in mice during normal aging
Baninameh, Z., Watzlawik, J. O., Hou, X., Richardson, T., Kurchaba, N. W., Yan, T., Florio, D. N. D., Fairweather, D., Kang, L., Nguyen, J. H., et al. (2024) · Autophagy Reports · doi:10.1080/27694127.2024.2434379 · Cited by 18
“…were performed in accordance with the Mayo Clinic Institutional Animal Care and Use Committee policies. pink1 −/− and prkn −/− mice (Jackson Laboratories, strains 017946 and 006582, respectively) [48,49] were backcrossed over 3 generations to a C57BL/6J background (Jackson Laboratories, 00664).”
Self-citationGómez‐López, S., Martínez-Silva, A. V., Montiel, T., Osorio‐Gómez, D., Bermúdez‐Rattoni, F., Massieu, L., & Escalante‐Alcalde, D. (2016) · Scientific Reports · doi:10.1038/srep24028 · Cited by 12
Human Brain Imaging of Dopamine Transporters
Varrone, A., & Halldin, C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418677-4.00009-9 · Cited by 16
Parkin deficiency perturbs striatal circuit dynamics
Baaske, M. K., Kramer, E. R., Meka, D. P., Engler, G., Engel, A. K., & Moll, C. K. E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104737 · Cited by 13
Is there a pathogenic role for mitochondria in Parkinson's disease?
Vives-Bauzá, C., de Vries, R. L. A., Tocilescu, M. A., & Przedborski, S. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70823-5 · Cited by 15
“However, no loss of dopaminergic neurons and, like in most patients with PARKIN mutations, no inclusion formations were noted in these mice [45].”
BackgroundSutherland, G. T., Mellick, G. D., Sue, C. M., Chan, D. K. Y., Rowe, D. B., Silburn, P. A., & Halliday, G. M. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.12.051 · Cited by 12
Autosomal Recessive Mutations in the Development of Parkinson‘s Disease
Lopez, G. J., & Sidransky, E. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.96 · Cited by 13
Mechanisms of mitophagy: putting the powerhouse into the doghouse
Riley, J. S., & Tait, S. W. G. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0137 · Cited by 14
“…examination of Parkin knockout mice reveals no overt motor phenotypes or signs of neurodegeneration, although this may relate to mice being short-lived animals that fail to accumulate sufficient damage to yield a phenotype (Goldberg et al., 2003; Perez and Palmiter, 2005; Kitada et al., 2009).”
BackgroundParkin regulates translesion DNA synthesis in response to UV radiation
Zhu, X., Ma, X., Tu, Y., Huang, M., Liu, H., Wang, F., Gong, J., Wang, J., Li, X., Chen, Q., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16855 · Cited by 12
“WT and Parkin−/− MEF cells were derived from 13.5 day-old WT and Parkin−/− [68] C57BL6/J mice embryo (The Jackson laboratory).”
InfluentialUnaltered α-synuclein blood levels in juvenile Parkinsonism with a parkin exon 4 deletion
Miller, D. W., Crawley, A., Gwinn, K. A., Lopez, G. J., Nussbaum, R. L., Cookson, M., Singleton, A., Hardy, J., & Doğu, O. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.053 · Cited by 12
Kim, J.-H., Yang, S., Kim, H., Vo, D.-K., Maeng, H., Jo, A., Shin, J. H., Shin, J., Baek, H., Lee, G. H., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00814-3 · Cited by 13
“However, parkin-knockout mice failed to produce any meaningful PD-related pathological features, such as dopamine neuron loss and Lewy body formation in the ventral mid-brains (VM) [6].”
The SMYD1 and skNAC transcription factors contribute to neurodegenerative diseases
Mayfield, R. D., Zhu, L., Smith, T. A., Tiwari, G. R., & Tucker, H. O. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100129 · Cited by 13
Rat models of major neurodegenerative disorders
Novati, A., Singer, E., Yu-Taeger, L., Clemensson, E. K. H., & Nguyen, H. P. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.19 · Cited by 13
Physiology versus pathology in Parkinson's disease
Nakamura, K., & Edwards, R. H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704254104 · Cited by 10
Animal Models for the Study of Human Neurodegenerative Diseases
Colpo, G. D., Ribeiro, F. M., Rocha, N. P., & Teixeira, A. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00042-5 · Cited by 14
Characterization of the Engrailed mutant mice as experimental models for Parkinson's disease
Sgadó, P., Viaggi, C., Fantacci, C., & Corsini, G. U. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.04.011 · Cited by 13
Animal Models of Parkinson's Disease
Dawson, V. L., & Dawson, T. M. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041644 · Cited by 12
Rehman, R., Dieffenbach, P. B., Vellarikkal, S. K., Corcoran, A. M., Pomales, L., Rubio, A. A., Zambrano-Vera, K., Spyropoulos, F., Kosmas, K., Lam, H., et al. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0349oc · Cited by 10
Self-citationCeravolo, R., Sgadó, P., Frosini, D., & Corsini, G. U. (2006) · Springer eBooks · doi:10.1007/978-3-211-33328-0_15 · Cited by 12
Aging, Parkinson’s Disease, and Models: What Are the Challenges?
Bellantuono, I., Mortiboys, H., Rocha, E. M., Chamoli, M., Chinta, S. J., Andersen, J. K., Wallis, R., Bézard, E., Goldberg, M., Greenamyre, T., et al. (2023) · doi:10.59368/agingbio.20230010 · Cited by 16
“Intriguingly, when a subgroup of DJ-1-KO mice were fully backcrossed onto a C57BL/6 background, they showed a severe early-onset (eight-week) unilateral loss of SN DA neurons but not VTA DA neurons, which gradually progressed to bilateral nigrostriatal degeneration at later ages.”
BackgroundSelf-citationModeling Nonmotor Symptoms of Parkinson’s Disease in Genetic Mouse Models
Fleming, S. M., & Chesselet, M. (2009) · Advances in behavioral biology · doi:10.1007/978-1-4419-0340-2_37 · Cited by 10
Self-citationMishra, R., & Upadhyay, A. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05668-y · Cited by 12
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease
Patel, J., Panicker, N., Dawson, V. L., & Dawson, T. M. (2022) · CNS Drugs · doi:10.1007/s40263-022-00973-7 · Cited by 9
Liu, Y., Jin, X., Li, C., Bu, J., Wang, B., Bai, M., Su, P., Xu, E., & Li, Y. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177091 · Cited by 12
Kreiner, G. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.09.006 · Cited by 9
Loss of HIPK2 Protects Neurons from Mitochondrial Toxins by Regulating Parkin Protein Turnover
Zhang, J., Shang, Y., Kamiya, S., Kotowski, S. J., Nakamura, K., & Huang, E. J. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.2017-19.2019 · Cited by 11
“Interestingly, Parkindeficient mice do not show any detectable degeneration in DA neurons (Goldberg et al., 2003; Von Coelln et al., 2004).”
BackgroundLoss of MINAR2 impairs motor function and causes Parkinson’s disease-like symptoms in mice
Ho, R., Amraei, R., Cena, K. D. L. D. L., Sutherland, E. G., Mortazavi, F., Stein, T., Chitalia, V., & Rahimi, N. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa047 · Cited by 7
“In addition, the spontaneous activity in cylinder and challenging beam tests, which are widely used methods to measure sensorimotor function in mouse models of Parkinson’s disease (Goldberg et al., 2003; Fleming et al., 2013), revealed that MINAR2 KO mice developed impairment in the sensorimotor function.”
MethodOf Parkin and Parkinson's: light and dark sides of a multifaceted E3 ubiquitin–protein ligase
Corti, O., & Brice, A. (2007) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2007.11.002 · Cited by 10
A novel role for parkin in trauma-induced central nervous system secondary injury
Mukhida, K., Kobayashi, N. R., & Méndez, I. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2004.12.020 · Cited by 10
“[39] generated these mice”
Lu, X. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)89002-8 · Cited by 11
Genetic causes of Parkinson’s disease: extending the pathway
Rieß, O., Krüger, R., Hochstrasser, H., Soehn, A. S., Nuber, S., Franck, T., & Berg, D. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_29 · Cited by 10
Rondeau, V., Kalogeraki, M., Roland, L., Nader, Z. A., Gourhand, V., Bonaud, A., Lemos, J. P., Khamyath, M., Moulin, C., Schell, B., et al. (2024) · Science Signaling · doi:10.1126/scisignal.adl5100 · Cited by 12
Lamberty, B. G., Estrella, L. D., Mattingly, J. E., Emanuel, K. M., Trease, A. J., Totusek, S., Sheldon, L., George, J. W., Almikhlafi, M. A., Farmer, T., et al. (2023) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2023.100656 · Cited by 13
Chen, X., 暨南大学广东省非人灵长类动物模型研究重点实验室, 中., Han, R., Liu, Y., Huang, W., Wang, Q., Xiong, X., Zhang, Y., Zhao, J., Li, S.-H., et al. (2023) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2023.241 · Cited by 10
State of the Art in Sub-Phenotyping Midbrain Dopamine Neurons
Basso, V., Döbrössy, M. D., Thompson, L. H., Kirik, D., Fuller, H. R., & Gates, M. A. (2024) · Biology · doi:10.3390/biology13090690 · Cited by 12
“These include models involving α - synuclein ( α -syn) [170], LRRK2 [171–173], PINK1 [174,175], parkin [176], and DJ-1 [177].”
BackgroundSARM1 loss protects retinal ganglion cells in a mouse model of autosomal dominant optic atrophy
Ding, C., Ndiaye, P. S., Campbell, S. R., Fry, M. Y., Gong, J., Wienbar, S. R., Gibbs, W., Morquette, P., Chao, L. H., Do, M. T. H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191315 · Cited by 8
Pathogenic insights to Parkin-linked model mice
Sato, S., Noda, S., & Hattori, N. (2020) · Neuroscience Research · doi:10.1016/j.neures.2020.03.014 · Cited by 9
Characterization of a Cul9–Parkin double knockout mouse model for Parkinson’s disease
Hollville, É., Joers, V. L., Nakamura, A., Swahari, V., Tansey, M. G., Moy, S. S., & Deshmukh, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-73854-y · Cited by 10
Behavioral profile in a Dctn1G71A knock-in mouse model of Perry disease
Deshimaru, M., Mishima, T., Watanabe, T., Kubota, K., Hosoi, M., Kinoshita-Kawada, M., Yuasa‐Kawada, J., Ikeda, M., Mori, M., Murata, Y., et al. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136234 · Cited by 8
Bareiss, S. K., Johnston, T., Lu, Q., & Tran, T. D. (2022) · Neuroscience Research · doi:10.1016/j.neures.2022.01.003 · Cited by 11
Animal Models and the Science of Movement Disorders
LeDoux, M. S. (2005) · Elsevier eBooks · doi:10.1016/b978-012088382-0/50003-7 · Cited by 11
Hattori, N., Machida, Y., Sato, S., Noda, K., Iijima-Kitami, M., Kubo, S., & Mizuno, Y. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_31 · Cited by 8
“Recently, two groups independently reported the generation of model mice lacking the parkin gene, which display certain abnormalities of dopamine metabolism (Itier et al., 2003; Goldberg et al., 2003).”
BackgroundWithout DJ-1, the D2 Receptor Doesn’t Play
Borrelli, E. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.004 · Cited by 8
Hernández-Baltazar, D., Nadella, R., Rovirosa-Hernández, M. D. J., Zavala-Flores, L. M., & Rosas-Jarquín, C. D. J. (2018) · InTech eBooks · doi:10.5772/intechopen.71271 · Cited by 12
Greenberg, D. A., & Jin, K. (2006) · International review of neurobiology · doi:10.1016/s0074-7742(06)77001-5 · Cited by 12
Ahnaou, A., & Drinkenburg, W. H. I. M. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104897 · Cited by 7
Neuroglia in neurodegeneration: Alzheimer, Parkinson, and Huntington disease
Lim, D., Matute, C., Cavaliere, F., & Verkhratsky, A. (2025) · Handbook of Clinical Neurology · doi:10.1016/b978-0-443-19102-2.00012-0 · Cited by 8
Kikkert, M., Hassink, G. C., & Wiertz, E. J. H. J. (2006) · Springer eBooks · doi:10.1007/3-540-28007-3_4 · Cited by 8
Foster, M. L., Bartnikas, T. B., Maresca-Fichter, H. C., Mercadante, C. J., Dash, M. E., Miller, C. E., & Dorman, D. C. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.10.002 · Cited by 9
“Mice deficient in the Park2 gene develop motor dysfunction and other neurologic effects during aging (Goldberg et al., 2003; Hennis et al., 2013, 2014; Kitada et al., 2009) and we hypothesize that they are an appropriate model to study gene and Mn interactions in PD.”
Sun, Z., Ma, X., Yang, H., Chen, S., He, S., Sun, R., Lu, H., & Zhang, J. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.05.015 · Cited by 7
Parkin-deficient rats are resistant to neurotoxicity of chronic high-dose methamphetamine
SHARMA, A. K., Bazylianska, V., & Moszczyńska, A. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113811 · Cited by 7
Esteca, M. V., Divino, I. A., da Silva, A. L. V., Severino, M. B., Braga, R. R., Ropelle, E. R., Simabuco, F. M., & Baptista, I. L. (2024) · Acta Physiologica · doi:10.1111/apha.14111 · Cited by 8
“The Parkin knockout animals were generated by Goldberg et al. 38 and provided by the Multidisciplinary Center for Biological Research in the Science of Animals Laboratory-CEMIB.”
MethodVarçin, M., Bentea, E., Mertens, B., den Haute, C. V., Baekelandt, V., Michotte, Y. M., & Sarre, S. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.07.004 · Cited by 7
Mitochondrial morphology and synaptic structure altered in the retina of parkin-deficient mice
Hu, Z.-X., Pu, J., Zheng, R., Yan, Y.-Q., Liu, K.-Y., Liu, Y., Zheng, R., Chen, Y., Lin, Z., Xue, N., et al. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136888 · Cited by 10
Mitochondria in the etiology of Parkinson's disease
Schapira, A. H. V. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83022-3 · Cited by 10
Epilepsy in Other Neurodegenerative Disorders: Huntington’s and Parkinson’s Diseases
Estrada‐Sánchez, A. M., Levine, M. S., & Cepeda, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804066-9.00073-0 · Cited by 13
Self-citationMitochondrial Injury: A Hot Spot for Parkinsonism and Parkinson's Disease?
Giasson, B. I. (2004) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2004.48.pe42 · Cited by 8
Molecular Pathogenesis, Experimental Models and New Therapeutic Strategies for Parkinson‘s Disease
Yamashita, H., & Matsumoto, M. (2007) · Regenerative Medicine · doi:10.2217/17460751.2.4.447 · Cited by 8
Role of glycogen synthase kinase-3 in l -DOPA-induced neurotoxicity
Koh, S., Kim, S. H., & Kim, H.-T. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903170663 · Cited by 7
“Parkindeficient mice have been reported to possess increased extracellular DA [39,40].”
Background5.3 Mitochondrial Production of Oxidants and Their Role in the Regulation of Cellular Processes
Brookes, P. S. (2007) · Springer eBooks · doi:10.1007/978-0-387-30411-3_19 · Cited by 7
Parkinson’s Disease and Parkin: Insights from Park2 Knockout Mice
Stephenson, S. E. M., Juliet, M., & Paul, J. (2012) · InTech eBooks · doi:10.5772/18148 · Cited by 6
Fiesel, F. C., Bustillos, B. A., Watzlawik, J. O., Chen, C., Berryer, M. H., Zhang, J., Boneski, P. K., Hayes, C. S., Bredenberg, J. M., Deneault, É., et al. (2025) · Autophagy · doi:10.1080/15548627.2025.2531025 · Cited by 9
“Homozygous and heterozygous Prkn W402A KI/KI as well as Prkn W402A KI/KI; pink1 −/− , pink1 −/− , and WT mice were bred on a C57BL/6 background as described previously [80,81].”
Self-citationQuaking but not parkin is the major tumor suppressor in 6q deleted region in glioblastoma
Yasar, F. B. A., Shingu, T., Zamler, D. B., Zaman, M. F., Chien, D., Zhang, Q., Ren, J., & HU, J. L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.931387 · Cited by 6
Non-Reproducibility of Oral Rotenone as a Model for Parkinson’s Disease in Mice
Niederberger, E., Wilken‐Schmitz, A., Manderscheid, C., Schreiber, Y., Gurke, R., & Tegeder, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012658 · Cited by 5
Mrohs, D., Rybarski, M. O., Andriske, M., Bohne, P., Mark, M. D., Lübbert, H., & Zhu, X. (2023) · Aging Pathobiology and Therapeutics · doi:10.31491/apt.2023.03.106 · Cited by 6
The Corticostriatal Pathway in Parkinson’s Disease
Bamford, N. S., & Cepeda, C. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-252-0_6 · Cited by 7
Self-citationAlterations in Corticostriatal Synaptic Function in Huntington's and Parkinson's Diseases
Cepeda, C., Bamford, N. S., André, V. M., & Levine, M. S. (2010) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-374767-9.00035-4 · Cited by 6
Self-citationSolving the Puzzle of Neurodegeneration
Wolfe, M. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00001-8 · Cited by 8
Kim, Y. S., Patel, S. S., & Lee, S. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.10.024 · Cited by 6
Ubiquitin-Dependent Protein Degradation
Hegde, A. N. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.02826-2 · Cited by 7
Kodsi, D. N. E., Tokarew, J. M., Sengupta, R., Lengacher, N. A., Ng, A. C., Boston, H., Jiang, Q., Palmberg, C., Pileggi, C. A., Shutinoski, B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.26.062380 · Cited by 7
Parkin characteristics and blood biomarkers of Parkinson’s disease in WPBLC study
He, H., Xiong, X., Zheng, Y., Hou, J., Jiang, T., Quan, W., Huang, J., Xu, J., Chen, K., Qian, J., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1511272 · Cited by 9
The Bac Transgenic Approach to Study Parkinson's Disease in Mice
Yang, X. W., & Lu, X. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00019-1 · Cited by 5
Mitochondrial DNA heteroplasmy rises in substantial nigra of aged PINK1 KO mice
Li, J., Xue, C., Gao, Q., Tan, J., & Wan, Z. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.112 · Cited by 5
Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse
Regoni, M., Zanetti, L., Comai, S., Mercatelli, D., Novello, S., Albanese, F., Croci, L., Consalez, G. G., Ciammola, A., Valtorta, F., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9050514 · Cited by 6
Modeling familial and sporadic Parkinson's disease in small fishes
Yamanaka, T., & Matsui, H. (2023) · Development Growth & Differentiation · doi:10.1111/dgd.12904 · Cited by 5
“Conversely, other studies failed to provide substantiating evidence of nigrostriatal degeneration, even in markedly aged mice (Goldberg et al., 2003; Itier et al., 2003; Noda et al., 2020; Perez & Palmiter, 2005).”
ResultTrease, A. J., Totusek, S., Lichter, E. Z., Stauch, K. L., & Fox, H. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126441 · Cited by 5
“Typically, monogenic Parkin-deficient mouse models do not show degenerative phenotypes [38–40].”
BackgroundFunctional Role of Parkin against Oxidative Stress in Neural Cells
Hwang, M., Lee, J.-M., Kim, Y., & Geum, D. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.1.62 · Cited by 5
Critical Role of PINK1 in Regulating Parkin Protein Levels In Vivo
Choo, Y. S., Tang, C., & Zhang, Z. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.95 · Cited by 5
Neuroinflammation as a Potential Mechanism Underlying Parkinsons Disease
Cebrián, C., & Sulzer, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803783-6.00008-0 · Cited by 11
Dapper, J. D., & Justice, M. J. (2005) · Movement Disorders · doi:10.1002/mds.20595 · Cited by 5
Mice Expressing Mutant Parkin Exhibit Hallmark Features of Parkinson's Disease
Hart, M. P., & Xu, A. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1719-09.2009 · Cited by 6
Current concepts on the etiology and pathogenesis of Parkinson disease
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00005-6 · Cited by 7
Phenotypical Characterization of Genetic Mouse Models of Parkinson Disease
Fleming, S. M., & Chesselet, M. (2005) · Elsevier eBooks · doi:10.1016/b978-012088382-0/50015-3 · Cited by 11
Self-citationWu, Z., Xiao, H., Kloeber, J. A., Ouyang, Y., Yin, P., Huang, J., Chen, B., Zhu, S., Lu, J., Han, Y., et al. (2025) · 癌症:英文版 · doi:10.1002/cac2.12648 · Cited by 4
Formation of seeding-competent α-synuclein aggregates in parkin-deficient iPSC-derived human neurons
Schmidt, S. I., Okarmus, J., Madsen, D. A., Hansen, J. S., Gregersen, E., Gram, H., Winkelmann, L. S., Oliveira, A. S., Heon‐Roberts, R., Ryan, B. J., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01038-4 · Cited by 5
“However, no association between parkin de fi ciency and α -Syn accumulation or aggregation has been reported in PD mouse models 38 – 40 , despite PARK2 knockout mice showing increased pSer129 α -Syn levels compared to WT mice upon α -Syn overexpression in the substantia nigra 41 .”
Metadata
- Authors
- Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., Gajendiran, M., Roth, B. L., Chesselet, M.-F., Maidment, N. T., Levine, M. S., & Shen, J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- Case Western Reserve University (US)
- Corresponding author
- Shen, Jie
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 278
- Issue
- 44
- Pages
- 43628-43635
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2088962120
- Cited by
- 913
- References
- 72
- Citations by year
- 2026: 8 · 2025: 25 · 2024: 35 · 2023: 27 · 2022: 45 · 2021: 39 · 2020: 39 · 2019: 25 · 2018: 39 · 2017: 40 · 2016: 29 · 2015: 34 · 2014: 41 · 2013: 43 · 2012: 36
- FWCI
- 33.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6206 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkin, Parkinson's disease, nigrostriatal pathway, dopaminergic neurons, substantia nigra, striatum, dopaminergic modulation, synaptic excitability, spiny neurons, E3 ubiquitin ligase, alpha-synuclein, synphilin-1, neuronal survival
- MeSH terms
- Alleles, Animals, Behavior, Animal, Brain, Chromatography, High Pressure Liquid, Disease Models, Animal, Dopamine, Electrophysiology, Mice, Transgenic, Models, Genetic, Neurons, Parkinson Disease, Receptors, Dopamine, Substantia Nigra, Time Factors, Blotting, Western, Germ-Line Mutation, Ubiquitin-Protein Ligases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.